Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kuldipsinh Zala"'
Autor:
Hardik Patel, Taufik Momin, Kevinkumar Kansagra, Harilal Patel, Chintan Shah, Ajaykumar Barot, Jay Bhavsar, Kuldipsinh Zala, Deven Parmar
Publikováno v:
Clinical pharmacology in drug developmentReferences.
This randomized, single-treatment, 2-sequence study evaluated the food effect on oral bioavailability of desidustat. Healthy adult male and female subjects were enrolled and randomly assigned to receive desidustat 50 mg orally in a fasting state in o
Autor:
Sishir, Gang, Prakash, Khetan, Deepak, Varade, Venkata Ramakrishna, Chinta, Siddharth, Mavani, Umesh, Gupta, S Venkata Krishna, Reddy, Sunil, Rajanna, Tarun, Jeloka, Vivek, Ruhela, Kevinkumar, Kansagra, Pooja, Kanani, Jayesh, Bhatt, Kuldipsinh, Zala
Publikováno v:
American journal of nephrology. 53(5)
A phase 3 study to assess the efficacy and safety of the desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, against the epoetin alfa for the treatment of anemia in patients with chronic kidney disease (CKD) with dialysis depen
Autor:
Dhananjai, Agrawal, Deepak, Varade, Hardik, Shah, Alm, Nazar, Jayakumar, Krishnan, Vineet, Shukla, Chinta, Ramakrishna, Mahel Chinthana, Bandara Galahitiyawa, Sidhharth B, Mavani, Sunil, Rajanna, Petkar, Jikki, Shamila, De Silva, Vivek, Ruhela, Parshottam, Koradia, Kevinkumar, Kansagra, Pooja, Kanani, Nitin, Sharma, Kuldipsinh, Zala, Deven, Parmar
Publikováno v:
American journal of nephrology. 53(5)
Desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being developed to treat anemia in patients with chronic kidney disease (CKD) without dialysis dependency.In total, 588 patients with a clinical diagnosis of anemia due to